Exclusive: Novo Nordisk allies itself with one of the buzziest groups in biotech, launching a multi-pronged attack at discovering new drugs
Novo Nordisk established its R&D rep around its in-house expertise that ultimately birthed the GLP-1 blockbuster semaglutide and pushed it to major-market franchise status. But its top execs have been crystal clear that the path to the future of R&D — moving past semaglutide on to the next big thing — points to more external alliances, marrying its global research arms in and out of Copenhagen with outside groups sparking headlines around their discovery work.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.